Stocklytics Platform
Asset logo for symbol RLYB
Rallybio Corporation
RLYB43
$1.100.00%$0.00
Penny Stock
Asset logo for symbol RLYB
RLYB43

$1.10

0.00%

Performance History

Chart placeholder
Key Stats
Open$1.11
Prev. Close$1.10
EPS-1.78
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$45.63M
PE Ratio-
LOWHIGH
Day Range1.11
1.11
52 Week Range1.08
5.00
Ratios
Revenue-
EBITDA Margin %-
EPS-1.78

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Rallybio Corporation (RLYB)

Rallybio Corporation (RLYB) is a biotechnology company that focuses on the discovery and development of breakthrough therapies for rare diseases. The company's mission is to bring hope to patients and their families by advancing innovative treatments that target the underlying causes of these diseases. With a strong pipeline of potential drug candidates, Rallybio Corporation is well-positioned to make a significant impact in the field of rare disease therapeutics.
The stock price history of Rallybio Corporation shows a steady upward trajectory since its initial public offering. Investors have been drawn to the promising potential of the company's drug candidates, which have shown positive results in preclinical and early-stage clinical trials. The stock has experienced some volatility in recent months, reflecting the broader market conditions and investor sentiment towards the biotechnology sector.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Stephen Uden M.B, M.D.
Headquarters
New Haven
Employees
45
Exchange
NASDAQ
add Rallybio Corporation to watchlist

Keep an eye on Rallybio Corporation

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the market capitalization of Rallybio Corporation (RLYB)?

Rallybio Corporation (RLYB) has a market capitalization of $45.64M. The average daily trading volume is 46.2K, indicating the stock's liquidity and investor engagement.
help

What is Rallybio Corporation's (RLYB) price per share?

The current price per share for Rallybio Corporation (RLYB) is $1.1. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Rallybio Corporation (RLYB)?

For Rallybio Corporation (RLYB), the 52-week high is $5, which is 354.55% from the current price. The 52-week low is $1.08, the current price is 1.85% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Rallybio Corporation (RLYB) a growth stock?

Rallybio Corporation (RLYB) has shown an average price growth of 0.41% over the past three years. It has received a score of 2 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Rallybio Corporation as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Rallybio Corporation (RLYB) stock price performance year to date (YTD)?

As of the latest data, Rallybio Corporation (RLYB) has a year-to-date price change of -54.17%. Over the past month, the stock has experienced a price change of -3.51%. Over the last three months, the change has been -28.57%. Over the past six months, the figure is -26.67%.
help

Is Rallybio Corporation (RLYB) a profitable company?

Rallybio Corporation (RLYB) has a net income of -$74.56M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -5.7K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$78.93M. Furthermore, the EBITDA is -$73.86M.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media